Secondary cytoreductive surgery in the patient with recurrent ovarian cancer is often beneficial.
The majority of women with ovarian cancer will present at an advanced stage and ultimately experience a recrudescence of tumor. Recent data indicates that secondary cytoreductive surgery is feasible, well tolerated and associated with significant prolongation of survival in selected patients with recurrent ovarian cancer.
Selman
Alberto E
AE
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Clinical Hospital, Universidad de Chile, Santiago, Chile.
Copeland
Larry J
LJ
D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000601:surgery*; D011379:Prognosis; D024162:Second-Look Surgery